ResearcherJapan Society for the Promotion of ScienceActive in the last 2 years
Nana Kimura
Matched on OpenAlex author ID A5101113114, A5158663620. Sources: OpenAlex.
Their work
- Papers
- 15 (first author 1, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 48
2020: 2 papers · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 10 papers · 2026: 1 paper
Papers 15
- Predictive Factors for Occult Metastases in Clinically M0 Pancreatic Cancer: A Prospective Multicenter Analysis of Staging Laparoscopy. Co-author DOI 10.1245/s10434-026-20728-8↗
- Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of trea… Co-author DOI 10.1007/s00535-024-02186-9↗
- Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probabi… Co-author DOI 10.1007/s00535-025-02215-1↗
- Successful conversion surgery for patients with pancreatic cancer, positive peritoneal cytology, and liver metastasis who were treated with chemotherapy involv… Co-author DOI 10.1007/s12328-025-02175-2↗
- Risk Factors for Early Liver Recurrence After Pancreatic Cancer Resection. First author DOI 10.1097/mpa.0000000000002441↗
- [Recent trends in multidisciplinary treatment for pancreatic cancer]. Last author DOI 10.11405/nisshoshi.122.803↗
- A multicenter prospective study to determine the optimal range of lymph node dissection in pancreatic cancer surgery after neoadjuvant chemotherapy (LYMRIN-Tri… Co-author DOI 10.1371/journal.pone.0325667↗
- Gastrojejunostomy for Asymptomatic Gastric Outlet Obstruction in Pancreatic Cancer May Contribute to Early Recovery. Co-author DOI 10.21873/anticanres.17618↗
- Novel CTC Detection Method in Patients with Pancreatic Cancer Using High-Resolution Image Scanning. Co-author DOI 10.3390/cancers17223640↗
- McKeown Esophagectomy for Esophageal Cancer Following Pancreaticoduodenectomy Using a Mesenteric Approach for Pancreatic Cancer: A Case Report. Co-author DOI 10.70352/scrj.cr.25-0204↗
- [Conversion Surgery for Pancreatic Cancer]. Co-author PMID 39957218↗
- Evaluating staging laparoscopy indications for pancreatic cancer based on resectability classification and treatment strategies for patients with positive peri… Co-author DOI 10.1002/ags3.12719↗
- Efficacy of staging laparoscopy for resectable pancreatic cancer on imaging and the therapeutic effect of systemic chemotherapy for positive peritoneal cytolog… Co-author DOI 10.1002/jhbp.1356↗
- [Recent trends of treatment for resectable pancreatic cancer]. Last author DOI 10.11405/nisshoshi.117.283↗
- Optimal Preoperative Multidisciplinary Treatment in Borderline Resectable Pancreatic Cancer. Co-author DOI 10.3390/cancers13010036↗
Closest collaborators
The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Tsutomu Fujii · 12 shared papers, 2020–2025 · strength 2.67
- Paper [Recent trends in multidisciplinary treatment for pancreatic cancer]. DOI 10.11405/nisshoshi.122.803↗
- Paper Successful conversion surgery for patients with pancreatic cancer, positive peritoneal cytology, and liver metastasis w… DOI 10.1007/s12328-025-02175-2↗
- Paper Risk Factors for Early Liver Recurrence After Pancreatic Cancer Resection. DOI 10.1097/mpa.0000000000002441↗
- Katsuhisa Hirano · 9 shared papers, 2020–2026 · strength 1.90
- Paper Successful conversion surgery for patients with pancreatic cancer, positive peritoneal cytology, and liver metastasis w… DOI 10.1007/s12328-025-02175-2↗
- Paper Risk Factors for Early Liver Recurrence After Pancreatic Cancer Resection. DOI 10.1097/mpa.0000000000002441↗
- Paper Gastrojejunostomy for Asymptomatic Gastric Outlet Obstruction in Pancreatic Cancer May Contribute to Early Recovery. DOI 10.21873/anticanres.17618↗
- Mina Fukasawa · 8 shared papers, 2023–2025 · strength 1.74
- Paper Successful conversion surgery for patients with pancreatic cancer, positive peritoneal cytology, and liver metastasis w… DOI 10.1007/s12328-025-02175-2↗
- Paper Risk Factors for Early Liver Recurrence After Pancreatic Cancer Resection. DOI 10.1097/mpa.0000000000002441↗
- Paper Gastrojejunostomy for Asymptomatic Gastric Outlet Obstruction in Pancreatic Cancer May Contribute to Early Recovery. DOI 10.21873/anticanres.17618↗
- Yoshihiro Shirai · 4 shared papers, 2025 · strength 0.93
- Paper Risk Factors for Early Liver Recurrence After Pancreatic Cancer Resection. DOI 10.1097/mpa.0000000000002441↗
- Paper Gastrojejunostomy for Asymptomatic Gastric Outlet Obstruction in Pancreatic Cancer May Contribute to Early Recovery. DOI 10.21873/anticanres.17618↗
- Paper A multicenter prospective study to determine the optimal range of lymph node dissection in pancreatic cancer surgery af… DOI 10.1371/journal.pone.0325667↗
- Ayaka Itoh · 4 shared papers, 2023–2025 · strength 0.86
- Paper Successful conversion surgery for patients with pancreatic cancer, positive peritoneal cytology, and liver metastasis w… DOI 10.1007/s12328-025-02175-2↗
- Paper A multicenter prospective study to determine the optimal range of lymph node dissection in pancreatic cancer surgery af… DOI 10.1371/journal.pone.0325667↗
- Paper Evaluating staging laparoscopy indications for pancreatic cancer based on resectability classification and treatment st… DOI 10.1002/ags3.12719↗
- Takamichi Igarashi · 3 shared papers, 2024–2026 · strength 0.69
- Paper Successful conversion surgery for patients with pancreatic cancer, positive peritoneal cytology, and liver metastasis w… DOI 10.1007/s12328-025-02175-2↗
- Paper Predictive Factors for Occult Metastases in Clinically M0 Pancreatic Cancer: A Prospective Multicenter Analysis of Stag… DOI 10.1245/s10434-026-20728-8↗
- Paper Evaluating staging laparoscopy indications for pancreatic cancer based on resectability classification and treatment st… DOI 10.1002/ags3.12719↗
- Haruyoshi Tanaka · 3 shared papers, 2023–2025 · strength 0.63
- Paper Risk Factors for Early Liver Recurrence After Pancreatic Cancer Resection. DOI 10.1097/mpa.0000000000002441↗
- Paper Evaluating staging laparoscopy indications for pancreatic cancer based on resectability classification and treatment st… DOI 10.1002/ags3.12719↗
- Paper Efficacy of staging laparoscopy for resectable pancreatic cancer on imaging and the therapeutic effect of systemic chem… DOI 10.1002/jhbp.1356↗
- Hiroaki Nagano · 3 shared papers, 2025 · strength 0.55
- Paper A multicenter prospective study to determine the optimal range of lymph node dissection in pancreatic cancer surgery af… DOI 10.1371/journal.pone.0325667↗
- Paper Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world… DOI 10.1007/s00535-024-02186-9↗
- Paper Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: … DOI 10.1007/s00535-025-02215-1↗
- Junji Furuse · 3 shared papers, 2025 · strength 0.55
- Paper A multicenter prospective study to determine the optimal range of lymph node dissection in pancreatic cancer surgery af… DOI 10.1371/journal.pone.0325667↗
- Paper Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world… DOI 10.1007/s00535-024-02186-9↗
- Paper Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: … DOI 10.1007/s00535-025-02215-1↗
- Makoto Ueno · 3 shared papers, 2025 · strength 0.55
- Paper A multicenter prospective study to determine the optimal range of lymph node dissection in pancreatic cancer surgery af… DOI 10.1371/journal.pone.0325667↗
- Paper Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world… DOI 10.1007/s00535-024-02186-9↗
- Paper Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: … DOI 10.1007/s00535-025-02215-1↗
- Takeshi Miwa · 3 shared papers, 2020–2025 · strength 0.49
- Paper McKeown Esophagectomy for Esophageal Cancer Following Pancreaticoduodenectomy Using a Mesenteric Approach for Pancreati… DOI 10.70352/scrj.cr.25-0204↗
- Paper Novel CTC Detection Method in Patients with Pancreatic Cancer Using High-Resolution Image Scanning. DOI 10.3390/cancers17223640↗
- Paper Optimal Preoperative Multidisciplinary Treatment in Borderline Resectable Pancreatic Cancer. DOI 10.3390/cancers13010036↗
- Kenichi Hirabayashi · 2 shared papers, 2023–2024 · strength 0.39
- Paper Evaluating staging laparoscopy indications for pancreatic cancer based on resectability classification and treatment st… DOI 10.1002/ags3.12719↗
- Paper Efficacy of staging laparoscopy for resectable pancreatic cancer on imaging and the therapeutic effect of systemic chem… DOI 10.1002/jhbp.1356↗
- Akinori Asagi · 2 shared papers, 2025 · strength 0.32
- Paper Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world… DOI 10.1007/s00535-024-02186-9↗
- Paper Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: … DOI 10.1007/s00535-025-02215-1↗
- Yohei Kitano · 2 shared papers, 2025 · strength 0.32
- Paper Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world… DOI 10.1007/s00535-024-02186-9↗
- Paper Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: … DOI 10.1007/s00535-025-02215-1↗
- Kunihiro Tsuji · 2 shared papers, 2025 · strength 0.32
- Paper Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world… DOI 10.1007/s00535-024-02186-9↗
- Paper Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: … DOI 10.1007/s00535-025-02215-1↗
- Kumiko Umemoto · 2 shared papers, 2025 · strength 0.32
- Paper Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world… DOI 10.1007/s00535-024-02186-9↗
- Paper Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: … DOI 10.1007/s00535-025-02215-1↗
- Takeshi Terashima · 2 shared papers, 2025 · strength 0.32
- Paper Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world… DOI 10.1007/s00535-024-02186-9↗
- Paper Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: … DOI 10.1007/s00535-025-02215-1↗
- Masayuki Ueno · 2 shared papers, 2025 · strength 0.32
- Paper Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world… DOI 10.1007/s00535-024-02186-9↗
- Paper Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: … DOI 10.1007/s00535-025-02215-1↗
- Satoshi Kobayashi · 2 shared papers, 2025 · strength 0.32
- Paper Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world… DOI 10.1007/s00535-024-02186-9↗
- Paper Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: … DOI 10.1007/s00535-025-02215-1↗
- Rei Suzuki · 2 shared papers, 2025 · strength 0.32
- Paper Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world… DOI 10.1007/s00535-024-02186-9↗
- Paper Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: … DOI 10.1007/s00535-025-02215-1↗
- Masafumi Ikeda · 2 shared papers, 2025 · strength 0.32
- Paper Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world… DOI 10.1007/s00535-024-02186-9↗
- Paper Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: … DOI 10.1007/s00535-025-02215-1↗
- Naohiro Okano · 2 shared papers, 2025 · strength 0.32
- Paper Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world… DOI 10.1007/s00535-024-02186-9↗
- Paper Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: … DOI 10.1007/s00535-025-02215-1↗
- Toshifumi Doi · 2 shared papers, 2025 · strength 0.32
- Paper Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world… DOI 10.1007/s00535-024-02186-9↗
- Paper Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: … DOI 10.1007/s00535-025-02215-1↗
- Reiko Ashida · 2 shared papers, 2025 · strength 0.32
- Paper Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world… DOI 10.1007/s00535-024-02186-9↗
- Paper Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: … DOI 10.1007/s00535-025-02215-1↗
- Kohei Nakachi · 2 shared papers, 2025 · strength 0.32
- Paper Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world… DOI 10.1007/s00535-024-02186-9↗
- Paper Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: … DOI 10.1007/s00535-025-02215-1↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.